source
- Analysts spot several biotech firms as likely M&A targets amid rising pharma deal activityPharma companies are actively looking for acquisition opportunities, and analysts have identified a handful of biotech firms that could be next in line for buyouts. Recent transactions have center…
- Only one third of US prostate cancer patients received pre-biopsy MRI in 2022, far below Western normsMRI is considered the standard pre-biopsy imaging tool for prostate cancer in most western nations, yet a new analysis shows that only about a third of US cases used it in 2022. In the United Stat…